Viking Therapeutics (VKTX) Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of VK2735
Go back to Viking Therapeutics (VKTX) Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of VK2735| ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) | Delayed: 32.01 -0.12 (0.37%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $32.13 | 52 Week High | $5.17 | |||
| Open | $32.26 | 52 Week Low | $0.94 | |||
| Day High | $33.05 | P/E | N/A | |||
| Day Low | $31.70 | EPS | $0.00 | |||
| Volume | 889,990 | |||||
